Clinical Study in the Treatment of Patients With COVID-19

Phase 3

• Conditions: COVID-19
• Interventions: Drug: Placebo; Drug: Molixan

• Registration Number: NCT04780672
• Lead Sponsor: Pharma VAM

Brief Summary

Multicenter, prospective, double-blind, placebo-controlled, randomized, parallel-group phase III study.

The study is designed for 2 treatment groups:

* Group 1 of the investigational drug - Patients receive standard therapy and the investigational drug.

* Group 2 of comparison - Patients receive standard therapy and placebo.

Detailed Description

Patients with the severe course of COVID-19 infection confirmed by PCR laboratory test will be involved in the study on a voluntary basis.

In accordance with regulatory enactments, these patients receive specialized medical care in specialized medical institutions, where the conduct of the study is planned.

The study is planned as a double-blind, which will be achieved by using Molixan and placebo (0.9% NaCl solution) in the same packaging with the same labeling, indistinguishable in color and smell.

Patients will be randomized in an unpredictable manner using the IWRS system.

It is planned to divide patients into 2 parallel groups:

1. Group 1. Standard therapy + Molixan;

2. Group 2. Standard therapy + placebo. The regimen (1 or 2) assigned to each study subject will not be known to either the Investigator or the patient.

Study Timeline

• Status Verified: 2021-02
• Study First Submitted: 2021-02-25
• Study First Submitted QC: 2021-03-02
• Study First Posted: 2021-03-03
• Study Start: 2021-03-09
• Last Update Submitted: 2021-10-08
• Last Update Posted: 2021-10-11
• Primary Completion: 2022-05-31
• Study Completion: 2022-09-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 330

Inclusion Criteria

1. Hospitalized male and female patients aged 18 to 75 and weighing no more than 120 kg inclusively with a diagnosis of the severe course of COVID-19 confirmed by the result of a laboratory study for the presence of SARS-CoV-2 RNA using nucleic acid amplification methods (to be performed on Screening, or results with sampling 72 hours prior to Screening may be accepted);

2. Changes in the lungs on CT (X-ray) typical for viral damage (the damage size is significant or subtotal; CT 3-4);

3. One or more criteria for a severe course:

   • RR > 30/min
   • SpO2 ≤ 93%
   • PaO2 /FiO2 ≤ 300 mm Hg
   • Decreased consciousness, agitation
   • Unstable hemodynamics (systolic blood pressure less than 90 mm Hg or diastolic blood pressure less than 60 mm Hg, urine output less than 20 ml/hour)
   • Arterial blood lactate > 2 mmol/l
   • qSOFA > 2 points

4. Signed informed consent of the patient to participate in the study*;

5. The patient's ability to adequately cooperate (the ability to understand the information provided about the clinical study, the willingness to comply with the requirements of the study protocol)*;

   *In case of impossibility of the criteria No. 4 and 5 fulfilling the decision on including the patient shall be taken by a medical council. After the normalization of the status the patient shall compulsorily be proposed to acquaint themselves with the Patient Information Leaflet and take a decision on further participation in the study (Informed Consent Form signing) or withdrawal.

6. For women with preserved reproductive function - a negative pregnancy test and consent to use adequate methods of contraception from the moment of inclusion in the study until the end of the study;

7. For men - consent to use adequate methods of contraception from the moment of inclusion in the study to the end of the study.

Non-inclusion criteria:

Patients cannot be included in the study if at least one of the following criteria is met:

Associated with the underlying disease:

1. Mild, moderate and extremely severe COVID-19 disease upon admission to the hospital;

2. A condition requiring invasive oxygen support;

3. Failure to meet the criteria for inclusion and severity of the condition in terms of the main parameters;

   Related to the investigational drug, prior and concomitant therapy:

4. Hypersensitivity or individual intolerance to the components of the investigational drug according to the history;

5. Taking any antiviral or immunomodulatory drugs after the manifestation of COVID-19 (except for those planned for appointment as part of the study);

   Associated with concomitant pathology:

   According to the history and physical examination:

6. A history of active tuberculosis;

7. Impossibility of intravenous administration of the drug;

8. Severe, decompensated or unstable somatic diseases according to the history and outpatient card/medical history:

   • Child-Pugh class B and C cirrhosis;
   • Myocardial infarction, CVA/TIA, PE less than 3 months before the start of the study, large aortic aneurysm (more than 6 cm);
   • Type 1 diabetes mellitus. Diseases of the thyroid gland with decompensation.
   • The presence of signs of severe damage to the central nervous system (history of severe TBI, meningitis, consequences of CVA, encephalopathy of various origin, epilepsy, etc.);
   • Current severe blood disorders or history of such diseases (i.e. baseline anemia Hb<80, myeloid leukemia, myelodysplastic syndrome, etc.);
   • No less than 3 months after the surgery for coronary artery bypass grafting/stenting before inclusion in the study;
   • Malignant neoplasm of any localization at present or within 5 years prior to inclusion in the study, with the exception of completely healed carcinoma in situ;

9. Any other comorbidities or conditions that, in the opinion of the investigator, make it difficult to interpret the results of treatment or may limit the patient's participation in the study;

   According to laboratory tests at screening:

10. A positive result for HIV, syphilis, hepatitis B and C at screening;

    Associated with the patient compliance in the study:

11. A history of alcohol abuse, drug dependence or drug addiction;

12. Patients who, in the opinion of the investigator, are obviously or likely to be unable to understand and evaluate the information on this study as part of the informed consent signing process, in particular regarding the expected risks and possible discomfort;

13. Patient's inability or unwillingness to follow the rules for conducting and participating in the clinical study;

14. Severe visual and/or hearing impairments, severe speech impairments and/or other abnormalities that may prevent the patient from adequately cooperating during the study;

15. A history of mental illness;

    Other:

16. Pregnancy;

17. Breast-feeding;

18. Participation in other clinical studies within 3 months prior to enrollment in this study.

Exclusion Criteria

1. Erroneous inclusion (violation of inclusion/non-inclusion criteria).
2. Individual intolerance to the investigational drug.
3. Refusal of the patient to continue participating in the study/withdrawal of informed consent by the patient.
4. Termination of the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Sol. of NaCl (Sodium chloride) - 0.9% Pharmacotherapeutic group: Regulators of water-electrolytic balance and acid-base balance. ATC: B05CB01 Sodium chloride
Molixan	Molixan	30 mg/ml solution for intravenous and intramuscular injection. Pharmacotherapeutic group: Metabolic agent. ATC code: V03AX - other medicinal products

Primary Outcome Measures

Name	Time	Method
WHO Ordinal Scale for Clinical Improvement	28 days	The median time to reach the clinical improvement on the WHO Ordinal Scale for Clinical Improvement (follow-up period 28 days after initiation of treatment) using hazard ratio estimates.

Secondary Outcome Measures

Name	Time	Method
Duration of hospitalization	28 days	Duration of hospitalization from the start of therapy, days (observation period of 28 days after the start of treatment)
Mechanical ventilation	28 days	The need for mechanical ventilation, extracorporeal membrane oxygenation, non-invasive ventilation or high-flow oxygen delivery by nasal cannula (observation period of 28 days after the start of treatment).
Invasive mechanical ventilation	28 days	The need for invasive mechanical ventilation of the lungs (observation period of 28 days after the start of treatment)
The transition of the disease to an extremely severe course	28 days	The frequency of the transition of the disease to an extremely severe course (observation period of 28 days after the start of treatment).
Fever	28 days	Duration of fever (≥38оC), days (observation period of 28 days after the start of treatment)
The dynamics of changes in the level of C-reactive protein	10 days	The dynamics of changes in the level of C-reactive protein compared with the baseline value (observation period of 10 days).
Stay in the intensive care unit	28 days	The need to stay in the intensive care unit (observation period of 28 days after the start of treatment).
The dynamics of the National Early Warning Score (NEWS)	10 days	The dynamics of the National Early Warning Score (NEWS) decrease in comparison with the baseline value (observation period of 10 days).; NEWS uses six physiological measurements: respiratory rate; oxygen saturation; temperature; systolic blood pressure; heart rate and level of consciousness. Each scores 0-3 and individual scores are added together for an overall score. An additional one points are added if the patient is receiving oxygen therapy.; Higher scores mean a worse outcome.
Mortality	28 days	All-cause mortality (follow-up period of 28 days after the start of treatment)
Time to cancellation of oxygen support	28 days	Time to cancellation of oxygen support, if available, days (observation period of 28 days after the start of treatment)
The dynamics of residual symptoms	28 days	The dynamics of residual symptoms on the 28th day after the start of treatment.
The dynamics of blood biochemical parameters	10 days	The dynamics of blood biochemical parameters in comparison with the initial value (observation period of 10 days) Any clinically significant deviations from laboratory parameters detected at visits after the first dosing of the drugs.; Biochemical blood assay: urea, creatinine, glucose, alanine aminotransferase, aspartate aminotransferase, bilirubin, albumin, lactate, lactate dehydrogenase, troponin, ferritin.; Local laboratories of research centers will be used for laboratory tests and assessments.; After collecting and verification 100% values of laboratory parameters according to the Protocol from all local laboratories, the units of measurement will be unified before Statistical process control by valid formulas for transitions.
The dynamics of CT signs	14 days	The dynamics of CT signs on the 14th day after the start of therapy compared with the baseline value.; In the conclusion CT study, a probabilistic assessment of the relationship of the detected changes with COVID 19 according to international recommendations and the approximate volume of lung damage according to the "empirical" scale of assessment shall be given.; The scale is based on a visual assessment of the approximate volume of compacted lung tissue in both lungs: 1. Absence of characteristic manifestations (CT-0) 2. Minimum volume/site \< 25% of lung volume (CT-1) 3. Average volume/site 25 - 50% of lung volume (CT-2) 4. Significant volume/site 50 - 75% of lung volume (CT-3) 5. Critical volume/site \> 75% of lung volume (CT-4).

Trial Locations

Locations (1)

Yaroslavl Regional Clinical Hospital for War Veterans - The International Center for the Elderly "Healthy Longevity"; 🇷🇺 Yaroslavl, Russian Federation